Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 85Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 48Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Stomach Neoplasms 16Melanoma 16Brenner Tumor 16Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 14Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Esophageal Squamous Cell Carcinoma 7Colorectal Neoplasms 7

Interventions

Gemcitabine 4Leucovorin 2Fluorouracil 2tremelimumab 1pamrevlumab 1irinotecan sucrosofate 1folfirinox 1durvalumab 1Taxes 1Specimen Handling 1Radiosurgery 1Oxaliplatin 1Medical Marijuana 1Irinotecan 1Heavy Ion Radiotherapy 1Chemoradiotherapy 1Capecitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Non-resectable × Taxes × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡